Deepening of lid sulcus from topical bimatoprost therapy

Optometry and Vision Science

Volumn 81, Issue 8, 2004, Pages 574-577

  Peplinski, Lee S ^a,c   Smith, Karen Albiani ^b  

^a Bennett and Bloom Eye Centers   (United States)

^b Smith Optometry   (United States)

^c NONE   (United States)

Author keywords

Adverse effect; Bimatoprost; Eyelid; Lid sulcus; Lumigan; Prostaglandin; Prostamide

Indexed keywords

DIAGNOSIS; EYE MOVEMENTS; PATIENT MONITORING; VISION AIDS;

BIMATOPROST THERAPY; HYPERTENSION; INTRAOCULAR PRESSURE; SIDE EFFECTS;

MEDICAL APPLICATIONS;

BIMATOPROST; BRIMONIDINE; LATANOPROST; PROSTAGLANDIN DERIVATIVE;

ADULT; AGED; ARTICLE; CASE REPORT; CATARACT EXTRACTION; CLINICAL EXAMINATION; CLINICAL FEATURE; EYELID; EYELID DISEASE; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; LID SULCUS DEEPENING; MALE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; EYELID DISEASES; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS;

EID: 4143078223     PISSN: 10405488     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.opx.0000141791.16683.4a     Document Type: Article

References (24)

1. Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol 1998;116:679-80.
2. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001;45(Suppl 4):S353-60.
3. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002;47(Suppl 1):S203-18.
4. Vogel R, Strahlman E, Rittenhouse KD. Adverse events associated with commonly used glaucoma drugs. Int Ophthalmol Clin 1999;39:107-24.
5. Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2002;19:231-48.
6. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol 2002;47 Suppl 1:S219.
7. Crevits L, Goethals M, Libbrecht N, Paemeleire K. Latanoprost in hemifacial spasm. Prostaglandins Other Lipid Mediat 2002;67:27-30.
8. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63.
9. Laibovitz RA, VanDenburgh AM, Felix C, David R, Batoosingh A, Rosenthal A, Cheetham J. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol 2001;119:994-1000.
10. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110-21.
11. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol 2002;47 Suppl 1:S105-15.
12. Robin AL. An accurate comparison of bimatoprost's efficacy and adverse effects. Arch Ophthalmol 2002;120:999-1000.
13. Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother 2002;36:504-11.
14. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol 1997;124:683-5.
15. Bito LZ, Salvador EV. Intraocular fluid dynamics. 3. The site and mechanism of prostaglandin transfer across the blood intraocular fluid barriers. Exp Eye Res 1972;14:233-41.
16. Miyake K, Ibaraki N, Goto Y, Oogiya S, Ishigaki J, Ota I, Miyake S. ESCRS Binkhorst lecture 2002: Pseudophakic preservative maculopathy. J Cataract Refract Surg 2003;29:1800-10.
17. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-52.
18. Wand M, Ritch R, Isbey EK, Jr., Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol 2001;119:614-5.
19. Mansberger SL, Cioffi GA. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol 2000;118:718-9.
20. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol 2002;47 Suppl 1:S185-202.
21. Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol 1999;127:531-6.
22. Kaufman HE, Varnell ED, Toshida H, Kanai A, Thompson HW, Bazan NG. Effects of topical unoprostone and latanoprost on acute and recurrent herpetic keratitis in the rabbit. Am J Ophthalmol 2001;131:643-6.
23. Fechtner RD, Khouri AS, Zimmerman TJ, Bullock J, Feldman R, Kulkarni P, Michael AJ, Realini T, Warwar R. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126:37-41.
24. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol 2001;119:300-1.